Nature Reviews Drug Discovery

Showing tau the exit

M. Teresa Villanueva Jan 01, 2025 pp. 16-16 10.1038/d41573-024-00200-6

Covalent inhibitor engages oncogenic AKT kinase

Alex Eccleston Jan 01, 2025 pp. 16-16 10.1038/d41573-024-00197-y

FDA approves first menin inhibitor, for acute leukaemia

Asher Mullard Jan 01, 2025 pp. 7-7 10.1038/d41573-024-00198-x

Multi-TACs target solid tumours

Sarah Crunkhorn Jan 01, 2025 pp. 17-17 10.1038/d41573-024-00193-2

ENGases to treat IgG-mediated diseases

Sarah Crunkhorn Jan 01, 2025 pp. 17-17 10.1038/d41573-024-00190-5

Author Correction: Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets

Lieselotte Vande Walle, Mohamed Lamkanfi Jan 01, 2025 pp. 72-72 10.1038/s41573-024-01104-1

Expanding the ligandable proteome

Sarah Crunkhorn Jan 01, 2025 pp. 17-17 10.1038/d41573-024-00192-3

Understanding cholestatic itch

Sarah Crunkhorn Jan 01, 2025 pp. 17-17 10.1038/d41573-024-00191-4

FDA approves first biparatopic antibody therapy

Asher Mullard Jan 01, 2025 pp. 7-7 10.1038/d41573-024-00189-y

Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights

Dennis S. W. Lee, Olga L. Rojas, Jennifer L. Gommerman Jan 01, 2025 pp. 72-72 10.1038/s41573-024-01103-2

FDA approves second TTR stabilizer for cardiac amyloidosis

Asher Mullard Jan 01, 2025 pp. 6-6 10.1038/d41573-024-00188-z

StitchR platform joins up gene therapy payloads

Katie Kingwell Jan 01, 2025 pp. 14-14 10.1038/d41573-024-00186-1

NK2R agonist delivers one-two punch to obesity

Sarah Crunkhorn Jan 01, 2025 pp. 15-15 10.1038/d41573-024-00185-2

FDA approves l-amino acid decarboxylase deficiency gene therapy

Asher Mullard Jan 01, 2025 pp. 6-6 10.1038/d41573-024-00184-3

Senescence as a therapeutic target in cancer and age-related diseases

Domhnall McHugh, Imanol Durán, Jesús Gil Jan 01, 2025 pp. 57-71 10.1038/s41573-024-01074-4

DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

Yvette Drew, Frank T Zenke, Nicola J Curtin Jan 01, 2025 pp. 19-39 10.1038/s41573-024-01060-w

The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap

Anneliene H. Jonker, Elena-Alexandra Tataru, Holm Graessner et al. Jan 01, 2025 pp. 40-56 10.1038/s41573-024-01059-3

Two decades of new drug approvals in Japan

Ryosuke Kuribayashi, Aya Hariu, Yasuhiro Kishioka et al. Jan 01, 2025 pp. 12-13 10.1038/d41573-024-00153-w

The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships

Josepine Fernow, Marie Olliver, William Couet et al. Jan 01, 2025 pp. 1-2 10.1038/d41573-024-00138-9

NaV1.8 inhibitor poised to provide opioid-free pain relief

Katie Kingwell Jan 01, 2025 pp. 3-5 10.1038/d41573-024-00203-3

Upcoming FDA approval decisions in Q1 2025

Kaniaw Dilzer Jan 01, 2025 pp. 9-9 10.1038/d41573-024-00202-4

Top product forecasts for 2025

Paul Verdin Jan 01, 2025 pp. 8-8 10.1038/d41573-024-00199-w

Can non-canonical amino acids open up non-canonical drug discovery opportunities?

Asher Mullard Jan 01, 2025 pp. 10-11 10.1038/d41573-024-00201-5